Company profile: Palvella Therapeutics
1.1 - Company Overview
Company description
- Provider of therapies for abandoned patient populations.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Palvella Therapeutics
Travere Therapeutics
HQ: United States
Website
- Description: Provider of drug discovery and development for catastrophic, debilitating and often life-threatening diseases, including a non-immunosuppressive medication developed for the treatment of IgA nephropathy, a rare kidney disorder.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Travere Therapeutics company profile →
Gain Therapeutics
HQ: United States
Website
- Description: Provider of pharmacological chaperone therapeutics for rare metabolic disorders and neurodegenerative diseases. Offers Magellan, an AI-supported 3D structural biology platform using supercomputer-powered models to identify novel allosteric binding sites, and allosteric protein regulation modalities. Pipeline includes GT-02287, a small-molecule for GBA-Parkinson’s disease, in Phase I.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Gain Therapeutics company profile →
Dynacure
HQ: France
Website
- Description: Provider of clinical-stage drug development focused on rare and orphan diseases, building a pipeline of novel antisense therapies. Offerings include DYN101, an investigational antisense medicine; danvatirsen (STAT3), in Phase 2 for HNSCC and Phase 1 for AML/MDS; FTX-001 (MALAT1), ready for clinical trials; and PEMDA-HN, a study of danvatirsen with pembrolizumab for recurrent/metastatic HNSCC.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Dynacure company profile →
eTherapeutics
HQ: United Kingdom
Website
- Description: Provider of drug discovery and development solutions using proprietary computational systems to analyze and predict medicine–cell interactions, optimizing efficacy and minimal side effects. Includes HepNet™ computational biology and GalOmic™ RNAi platforms, with candidates ETX-312 (MASH), ETX-407 (dAMD), ETX-148 (haemophilia), and ETX-291 (cardiometabolic).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full eTherapeutics company profile →
Phathom Pharmaceuticals
HQ: United States
Website
- Description: Provider of biopharmaceutical development focused on vonoprazan, a potassium-competitive acid blocker under clinical study for acid-related gastrointestinal disorders, including GERD and H. pylori. Activities include the pHalcon-NERD Phase 2 on-demand and Phase 3 daily dosing trials for NERD, and an Expanded Access Policy (no products currently available through this program).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Phathom Pharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Palvella Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Palvella Therapeutics
2.2 - Growth funds investing in similar companies to Palvella Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Palvella Therapeutics
4.2 - Public trading comparable groups for Palvella Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →